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Abstract
Background: One of the major mechanisms that could produce resistance to antineoplastic drugs in cancer cells is the ATP
binding cassette (ABC) transporters. The ABC transporters can significantly decrease the intracellular concentration of
antineoplastic drugs by increasing their efflux, thereby lowering the cytotoxic activity of antineoplastic drugs. One of these
transporters, the multiple resistant protein 7 (MRP7, ABCC10), has recently been shown to produce resistance to
antineoplastic drugs by increasing the efflux of paclitaxel. In this study, we examined the effects of BCR-Abl tyrosine kinase
inhibitors imatinib, nilotinib and dasatinib on the activity and expression of MRP7 in HEK293 cells transfected with MRP7,
designated HEK-MRP7-2.
Methodology and/or Principal Findings: We report for the first time that imatinib and nilotinib reversed MRP7-mediated
multidrug resistance. Our MTT assay results indicated that MRP7 expression in HEK-MRP7-2 cells was not significantly altered
by incubation with 5 mM of imatinib or nilotinib for up to 72 hours. In addition, imatinib and nilotinib (1-5 mM) produced a
significant concentration-dependent reversal of MRP7-mediated multidrug resistance by enhancing the sensitivity of HEK-
MRP7-2 cells to paclitaxel and vincristine. Imatinib and nilotinib, at 5 mM, significantly increased the accumulation of [
3H]-
paclitaxel in HEK-MRP7-2 cells. The incubation of the HEK-MRP7-2 cells with imatinib or nilotinib (5 mM) also significantly
inhibited the efflux of paclitaxel.
Conclusions: Imatinib and nilotinib reverse MRP7-mediated paclitaxel resistance, most likely due to their inhibition of the
efflux of paclitaxel via MRP7. These findings suggest that imatinib or nilotinib, in combination with other antineoplastic
drugs, may be useful in the treatment of certain resistant cancers.
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Introduction
Although the clinical use of surgery, radiation and chemotherapy
have decreased the recurrence rates of cancer, cellular resistance to
chemotherapeutic drugs is a major obstacle in the treatment of cancer
[1,2]. The efficacy of chemotherapy can be limited due to acquired
resistance from previous treatment. Consequently, research strategies
to circumvent such resistance in cancer cells have become a current
focus for the development of novel combinational chemotherapeutic
strategies. Both intrinsic and acquired drug resistance can produce
multiple changes in various cellular pathways, leading to a decrease in
the cytotoxicity, and thus the efficacy, of antineoplastic drugs [3].
Therefore, cancer patients that receive multiple treatments can
become increasingly insensitive to chemotherapeutic agents.
One of the primary cellular mechanisms that can produce
resistance to antineoplastic therapy involves the efflux of drugs
from the cancer cells by specific transmembrane transporters or
pumps [4]. These transporter proteins originate from the
superfamily of ATP-binding cassette (ABC) transporters that share
common structural and functional properties [5]. A number of
studies have shown that the majority of the members of the C
family of ABC transporters are multidrug resistance proteins
(MRPs), which are characterized by cross-resistance to many
structurally unrelated drugs [2,4].
A number of studies suggest that cancer cells that express the
ABC C family transporter MRP7/ABCC10 can develop resis-
tance to various chemotherapeutic drugs. For example, human
salivary gland adenocarcinoma (SGA) cells that overexpress
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resistance to vincristine [6]. MRP7 expression has also been
immunohistochemically identified in tumor-bearing mice xeno-
grafted with human SGA following treatment with vincristine [6].
Furthermore, E217bG, a competitive inhibitor of MRP7 transport,
significantly decreased docetaxel accumulation in human SGA
cells [6]. Overall, compounds that are inhibitors of MRP7
transport activity attenuate or reverse resistance in cancer cells
that express the MRP7 protein.
The MRP7-overexpressing cells confer resistance to several
anticancer drugs including paclitaxel, vincristine and vinblastine
[7]. Recent papers also reported that MRP7-overexpresssing cells
confer resistance to nucleoside analogues and epithilone B [8].
Previously, in our laboratory, we have shown that cepharanthine,
a biscoclaurine-derived alkaloid, reversed MRP7-mediated pacli-
taxel resistance [9].
Tyrosine kinase inhibitors (TKIs) can reverse the resistance of
cancer cells to antineoplastic drugs through multiple mechanisms.
For example, in human SGA cells, MRP7, P-gp, and MRP1 were
all detected after prolonged exposure to vincristine [6]. Recently,
we and others have reported that some of the TKIs are potent
modulators of ABC transporters, including P-gp and BCRP/
ABCG2 [10,11]. Recent results from our laboratory suggested that
nilotinib significantly reverses P-gp- and BCRP-mediated MDR
[12].
In this study, one of the main goals was to identify TKI
compounds that would reverse MRP7-mediated drug resistance.
Consequently, it is possible that TKIs, in combination with other
antineoplastic drugs, may be useful in the treatment of cancers that
express MDR proteins, including the ABC transporters. An
important discovery about TKIs was that certain so-called ‘‘small
molecule’’ drugs could inhibit TK activity by competing with ATP
for binding to the intracellular catalytic domain of receptor TKs,
which produced inhibition of various downstream signaling
cascades by autophosphorylation [13]. Interestingly, imatinib,
nilotinib and dasatinib are inhibitors of the TK breakpoint cluster
region- Abelson (BCR-Abl) and KIT, a class III receptor TK
[14–18]. The BCR-Abl gene is associated with a dysregulation of
TK function and subsequently leads to malignant transformation
in chronic myelogenous leukemia (CML) [19,20]. The recognition
of BCR-Abl gene and its corresponding protein has led to the
development of small-molecule drugs designed to block the
activation of BCR-Abl TKIs through competitive binding at the
ATP-binding site [19]. Overall, the primary aim of this study was
to determine if the BCR-Abl TKIs could reverse MRP7-mediated
MDR.
Materials and Methods
2.1. Cell lines
HEK293 cells and the MRP7 cDNA were generously provided
by Dr. Gary Kruh (University of Illinois at Chicago, Chicago, IL).
The transfected HEK-MRP7-2 cells and empty vector transfected
HEK293-pcDNA3.1 cells were established from HEK293 cells
through electroporation [9]. The parental drug-sensitive human
epidermoid carcinoma cell line KB-3-1 and its corresponding P-
gp-overexpressing cell line KB-C2 were kindly provided by Drs.
Gottesman (NCI, Bethesda, MD) and Akiyama (Kagoshima
University, Japan), respectively. The KB-C2 cells were established
from KB-3-1 cells by exposing them to increasing concentrations
of colchicine in a gradual step-wise manner (up to 2 mg/ml) and
harvesting the cells that were resistant [20]. All of these cell lines
were grown as adherent monolayers in flasks with Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
bovine serum, 2 mM glutamine, 100 units/ml penicillin, and
100 mg/ml streptomycin under standard cell culturing conditions
in a humidified incubator containing 5% CO2 at 37uC.
2.2. Materials
DMEM, bovine serum and penicillin/streptomycin were
purchased from Hyclone (Logan, UT). Nilotinib (TasignaH)
(Fig. 1B) was obtained as a gift from Novartis pharmaceuticals
(Basel, Switzerland). Imatinib (Fig. 1A) and dasatinib (Fig. 1C)
were purchased from ChemieTeck Inc. (Indianapolis, IN).
Paclitaxel, vincristine, doxorubicin, colchicine, p-aminophenyl-
methylsulfonyl fluoride, bovine serum albumin, dimethyl sulfoxide
(DMSO) and 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan
(MTT), the polyclonal goat antibody against MRP7 (C-19), the
monoclonal mouse antibody against P-gp (P7965), the secondary
horseradish peroxidase-labeled anti-goat or anti-mouse IgG were
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). A
polyclonal antibody against human MRP1/ABCC1 was kindly
provided by Dr. Akiyama (Kagoshima University, Japan) [21]. A
monoclonal antibody BXP-34 against BCRP was acquired from
Signet Laboratories Inc. (Dedham, MA). [
3H]-paclitaxel (45 mCi/
mmol) was purchased from Moravek Biochemicals (Brea, CA).
2.3. Preparation of cell lysates
Confluentmonolayer cells inT-25flaskwere harvested andrinsed
twice with cold PBS. The cell extracts were prepared using the
Radioimmunoprecipitationassaybuffer[16PBS,1%NonidetP-40,
0.5% sodium deoxycholate, 0.1% SDS, 100 mM p-APMSF, 10 mM
leupeptin, and 10 mM aprotinin] for 30 min on ice with occasional
Figure 1. Chemical structures of imatinib (A), nilotinib (B), and dasatinib (C).
doi:10.1371/journal.pone.0007520.g001
Reversal of MDR by TKIs
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7520rocking followed by centrifugation at 12,000 rpm at 4uC for 15 min.
The protein concentrations of cell lysates were determined by the
Bradford protein assay [22]. The supernatant containing total cell
lysates were collected and stored at 280uC until use.
2.4. Immunoblotting
Equal amount of total cell lysates (40 mg) were resolved by 4–
12% sodium dodecyl sulfate polycrylamide gel electrophoresis
(SDS-PAGE) and electrophoretically transferred onto nitrocellu-
lose membranes [23]. The cell lysates were denatured in a 100uC
water beaker for 5 min before loading onto the 4–12% SDS-
PAGE. The gel was run in the SDS electrophoresis buffer (25 mM
Tris base, 0.192 M glycine, 1% SDS) at 170 V for 2 h. The
transfer was performed in a transfer buffer (25 mM Tris base,
0.192 M glycine, PH 8.3) at 30 V for 2 h. The nitrocellulose
membrane was then immersed in 5% skim milk to block
nonspecific binding for 1 h at room temperature. The membrane
was then immunoblotted overnight with primary antibodies
(polyclonal MRP7 or monoclonal P-gp and BCRP antibodies at
1:500 and polyclonal MRP1 at 1:3,000) at 4uC. The following day,
the membrane was washed three times with TBST buffer (0.3%
Tris, 0.8% NaCl, 0.02% KCl, 0.05% Tween 20) followed by a
three-hour incubation with secondary antibodies of polyclonal
anti-MRP7 or monoclonal anti-P-gp at 1:1000. The protein-
antibody complex was measured using an enhanced chemilumi-
nescence detection system (Amersham, NJ). The membrane was
then exposed to the film for development. The conventionally used
loading control actin was used to detect equal loading in each lane
in the samples prepared from cell lysates.
2.5. Analysis of drug sensitivity
Drug sensitivity was analyzed using a slightly modified MTT
colorimetric assay [23]. Empty vector transfected HEK293-
pcDNA3.1 cells and MRP7-transfected HEK293-MRP7-2 cells
were seeded in 96-well plates in triplicate at 5000 cells/well. After
incubation in DMEM supplemented with 10% bovine serum at
37uC for 24 h, the antineoplastic drugs were diluted to various
concentrations and incubated with the cells continuously for 72 h.
The potential inhibitors were added 1 h prior to the addition of
the anticancer drugs.
After drug incubation of 72 h, 20 ml MTT (4 mg/ml) was
added to each well and the plate was further incubated for 4 h,
allowing viable cells to develop from the yellow-colored MTT into
dark-blue formazan crystals. Subsequently, the medium was gently
removed without agitating the adhesive monolayer of cells, and
100 ml of DMSO was added into each well to dissolve the
formazan crystals. The plates were well shaken for 5 min, and an
OPSYS microplate reader read the absorbance at 570 nm from
DYNEX Technologies Inc. (Chantilly, VA). The degree of
resistance was calculated by dividing the IC50 for the MDR cells
by that of the parental cells, whereas the degree of MDR reversal
was calculated by dividing the IC50 of the cells with the anticancer
drug in the absence of inhibitor by that obtained in the presence of
the inhibitor. The concentrations required to inhibit growth by
50% of the control cells were calculated from survival curves using
the Bliss method [23].
The antineoplastic drugs used included paclitaxel, vincristine
and doxorubicin at varying concentrations up to a final
concentration of 10, 1, and 1 mM, respectively. The BCR-Abl
TKIs, such as nilotinib and imatinib, were subsequently used at
nontoxic concentrations of 1, 2.5 and 5 mM to screen against
vincristine and doxorubicin. In this study, we first selected a single
nontoxic dose (5 mM) to examine the effects of TKIs on MRP7-
mediated resistance to paclitaxel. Once we determined which
TKIs had the most significant reversal effect, such as imatinib and
nilotinib, we subsequently selected three concentrations (1, 2.5 or
5 mM) for each TKI to determine whether their reversal effects
were concentration-dependent to paclitaxel, vincristine and
doxorubicin.
2.6. Drug accumulation and efflux
The HEK293-pcDNA3.1 parental cells and HEK-MRP7-2
transfected cells were seeded in two T75 flasks and incubated with
DMEM supplemented with 10% bovine serum at 37uC. After the
cellswere60to95%confluent,eachinhibitorwasadded to separate
flasks and the cells were incubated for 1 h. The cells were then
trypsinized and two aliquots (48610
6 cells) from each cell line were
suspended in the medium. Subsequently, cells were suspended in
the medium containing [
3H]-paclitaxel at a concentration of
0.1 mM with or without the TKIs nilotinib and imatinib (5 mM)
for 1 h at 37uC. One hour later, the incubation medium was
replaced by the medium containing the TKIs without paclitaxel.
Aliquots (1610
6 cells) were collected at various time points (0, 20,
60, and 120 min). The cells were then washed with ice-cold PBS
and each sample was placed in scintillation fluid to measure the
radioactivity in a Packard TRI-CARB 1900CA liquid scintillation
counter from Packard Instrument Inc. (Downers Grove, IL).
2.7. Statistical analysis
All experiments were repeated at least three times and the
differences were determined by two-tailed Student’s t-test. The a
priori statistical significance was set at P,0.05.
Results
3.1. Expression of MRP7 in HEK293-pcDNA3.1 and HEK-
MRP7-2 cells
In this study, the two cell lines utilized were HEK293 cells
transfected with either the MRP7 expression vector or the empty
vector control (pcDNA3.1). Immunoblot analysis was performed
to detect the expression level of MRP7 protein in the
aforementioned lines. MRP7 protein (MW 171 kD) was expressed
in HEK-MRP7-2 cells, but not in HEK293-pcDNA3.1 cells
(Fig. 2A). P-gp, with a molecular weight of 170 kD, was detected in
the positive control KB-C2 cell lines, but not in the negative
control KB-3-1, HEK293-pcDNA3.1 or HEK-MRP7-2 cell lines
(Fig. 2B). We also conducted Western blot experiments to
determine if MRP1 and BCRP were expressed in HEK293-
pcDNA3.1 and HEK-MRP7-2 cells. The levels of MRP1 and
BCRP in both HEK-MRP7-2 cells and HEK293-pcDNA3.1 cells
were undetectable. These findings are important, as any effects
observed with the inhibitors are unlikely to be due to their
interaction with P-gp, MRP1 and/or BCRP.
To evaluate the effect of imatinib/nilotinib on the expression of
MRP7, the HEK-MRP7-2 cells were incubated with 5 mMo f
imatinib or nilotinib for 36 and 72 h, respectively. The incubation
of HEK-MRP7-2 cells with imatinib or nilotinib did not
significantly alter the expression of the protein levels of MRP7
at different time points (Fig. 2C and D). This suggests that the
effect of the inhibitors on the response of cells to the anticancer
drugs is not due to the regulation of MRP7 expression.
3.2. Analysis of the drug sensitivity of MRP7-transfected
HEK293 cells.
To determine the drug resistance profile of MRP7, the sensitivity
of HEK-MRP7-2 transfected cells to specific antineoplastic drugs
was compared to that of the vector-only control cells, HEK293-
Reversal of MDR by TKIs
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level of resistance to paclitaxel and vincristine (9.5- and 6.7-fold
resistancecomparetothe controlcells,respectively)(Table1).These
results indicated that the HEK-MRP7-2 cell line was able to confer
resistance to various antineoplastic drugs, which is consistent with
our previous report [9].
3.3. The effect of TKIs on sensitivity of MRP7-transfected
HEK293 cells to anticancer drugs
We tested several BCR-Abl TKIs to determine if they could
reverse the resistance of HEK293 cells overexpressing MRP7 to
the antineoplastic drug paclitaxel and vincristine. The magnitude
of reversal produced by the TKIs to paclitaxel was variable
(Table 1; Fig. 3). The preincubation of cells with imatinib or
nilotinib, at 2.5 mM, significantly reversed the resistance of HEK-
MRP7-2 cells to paclitaxel (Table 1, Fig. 3A and 3B). Imatinib and
nilotinib produced a 6.9- and 13.0-fold reversal, respectively, of
the resistance to paclitaxel. The IC50 of paclitaxel in HEK-MRP7-
2 cells co-cultured with 2.5 mM of nilotinib was significantly
decreased from 207.0619.7 nM to 15.960.9 nM, and this was
significantly lower than that of paclitaxel in the control group
(21.961.9 nM). The resistance to paclitaxel was completely
reversed when imatinib was co-incubated with paclitaxel in
HEK-MRP7-2 cells. A significantly greater reversal was obtained
at the 5 mM (12.4-fold) compared to the 1 mM (4.7-fold)
concentration. Imatinib, at 5 mM, also increased the sensitivity
of cells to paclitaxel in HEK293-pcDNA3.1 cells by 2.2-fold,
although this effect in HEK293-pcDNA3.1 was significantly lower
than that in the MRP7 transfected cells (12.5-fold) (Table 1). These
results indicated that the BCR-Abl TKIs imatinib and nilotinib
significantly attenuated the resistance to paclitaxel mediated by
MRP7. Although the co-incubation of HEK293-pcDNA3.1
(control cells) with nilotinib and paclitaxel also enhanced the
sensitivity to paclitaxel (a 2.5-fold shift in HEK293-pcDNA3.1
cells), this enhanced sensitivity was significantly lower than that
determined for the MRP7 transfected cells (Table 1; Fig. 3C). In
contrast, another BCR-Abl TKI, dasatinib at 2.5 mM, did not
significantly enhance paclitaxel sensitivity in either HEK293-
pcDNA3.1 or HEK-MRP7-2 cells (Table 1, Fig. 3C).
In addition to paclitaxel, we also examined the effect of the
selected TKIs to sensitize cells to another anticancer drug,
vincristine. Similar to the findings with paclitaxel, nilotinib and
Figure 2. Immunoblot detection of MRP7 and P-gp and the effect of imatinib or nilotinib on MRP7 expression. (A) Expression of MRP7
in HEK293-pcDNA3.1 (lane 1) and MRP7-transfected cells (lane 2). (B) Expression of P-gp in HEK293-pcDNA3.1 (lane 1), HEK-MRP7-2 (lane 2), KB-3-1
(lane 3) and KB-C2 cells (lane 4). (C) Effect of 5 mM of imatinib on the expression level of MRP7 (HEK-MRP7-2) for 36 and 72 h, respectively. (D) Effect
of 5 mM of nilotinib on the expression level of MRP7 (HEK-MRP7-2) for 36 and 72 h, respectively. Equal amounts (40 mg protein) of total cell lysate
were used for each sample. The nitrocellulose membranes were immunoblotted with primary antibody against MRP7 or actin at 1:500 dilution, or P-
gp at 1:500 dilution at 4uC overnight, and then incubated with HRP-conjugated secondary antibody at 1:1000 dilutions at room temperature for 3 h.
doi:10.1371/journal.pone.0007520.g002
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vincristine resistance (2.1-, 6.8- and 9.0-fold, respectively, for
nilotinib; 2.4-, 6.9- and 8.2-fold, respectively, for imatinib) in a
concentration-dependent manner (Table 1). We also examined the
response of MRP7-transfected cells to another anticancer drug,
doxorubicin, in the presence of imatinib, as doxorubicin is not a
substrate of MRP7 [23]. Our results indicated that imatinib (1, 2.5
and 5 mM) did not significantly sensitize the response of control
parental HEK293-pcDNA3.1 cells, or reverse resistance in HEK-
MRP7-2 transfected cells, (Table 1) to doxorubicin. This indicates
that the response to these TKIs was specific for MRP7, as
doxorubicin is not a substrate for MRP7 and thus would not
mediate doxorubicin efflux. Doxorubicin is a substrate of P-gp,
MRP1 and BCRP, but neither imatinib nor nilotinib significantly
increased doxorubicin sensitivity of HEK-MRP7-2 cells, suggest-
ing that P-gp, MRP and BCRP do not significantly contribute to
the drug resistance of HEK-MRP7-2.
Overall, imatinib and nilotinib significantly reversed MRP7-
mediated resistance to paclitaxel and vincristine, but not doxoru-
bicin. Furthermore, this reversal was concentration-dependent
(Table 1; Fig. 3). Although an increase in the sensitization of the
HEK293-pcDNA3.1 control cells occurred upon exposure to
nilotinib or imatinib, this effect was significantly lower than that
determined for the HEK-MRP7-2 transfected cells (Table 1; Fig. 3).
3.4. The effects of imatinib and nilotinib on the
intracellular accumulation and efflux of [
3H]-paclitaxel
In order to determine the mechanism by which imatinib and
nilotinib surmount or reverse MRP7-mediated paclitaxel resis-
tance, their effect on the accumulation of [
3H]-paclitaxel in
MRP7-transfected cells was examined. The intracellular concen-
tration of [
3H]-paclitaxel in HEK-MRP7-2 cells was 30% of that
accumulated by the HEK293-pcDNA3.1 cells (Fig. 4). The
accumulation of paclitaxel was significantly enhanced (1.9-fold)
in HEK-MRP7-2 cells (P,0.05) following incubation of cells with
either imatinib or nilotinib at a concentration of 5 mM. In
HEK293-pcDNA3.1 cells, imatinib, but not nilotinib, had resulted
in a slight increase in the intracellular concentration of [
3H]-
paclitaxel, but this sensitization was modest compared to the effect
of imatinib in HEK-MRP7-2 cells.
Based on the above results, it is possible that the increase in
intracellular paclitaxel produced by imatinib and nilotinib could be
Table 1. The effect of nilotinib, imatinib and dasatinib on the sensitivity of HEK293-pcDNA3.1 and HEK-MRP7-2 cells to paclitaxel,
vincristine and doxorubicin.
HEK293-pcDNA3.1 HEK-MRP7-2
Compound IC50 6 SD
a (nM) RF
b DMF
c IC50 6 SD
a (nM) RF
b DMF
c
Paclitaxel 21.85 6 1.89 (1.00) 207.03 6 19.69 (9.47)
+ Nilotinib 1 mM 10.15 6 0.94 (0.46) 2.15 26.34 6 1.34 (1.21) 7.86 *
+ Nilotinib 2.5 mM 8.61 6 0.32 (0.39) 2.54 15.87 6 0.94 (0.73) 13.05 **
+ Nilotinib 5 mM 7.63 6 0.15 (0.35) 2.86 9.90 6 0.42 (0.45) 20.91 **
+ Imatinib 1 mM 16.17 6 0.77 (0.74) 1.35 44.43 6 2.07 (2.03) 4.66 *
+ Imatinib 2.5 mM 13.70 6 0.82 (0.63) 1.59 22.75 6 2.36 (1.04) 9.10 *
+ Imatinib 5 mM 9.76 6 0.82 (0.45) 2.24 16.63 6 2.36 (0.76) 12.45 **
+ Dasatinib 2.5 mM 19.87 6 0.94 (0.91) 1.10 204.11 6 13.45 (9.34) 1.01
Vincristine 9.86 6 1.89 (1.00) 66.38 6 9.69 (6.73)
+ Nilotinib 1 mM 8.40 6 0.10 (0.85) 1.17 31.73 6 0.91 (3.22) 2.09
+ Nilotinib 2.5 mM 7.60 6 0.32 (0.77) 1.30 9.71 6 1.44 (0.98) 6.84 *
+ Nilotinib 5 mM 6.64 6 2.46 (0.67) 1.48 7.39 6 0.77 (0.75) 8.98 *
+ Imatinib 1 mM 7.33 6 0.75 (0.74) 1.35 27.16 6 2.02 (2.75) 2.44
+ Imatinib 2.5 mM 7.08 6 0.82 (0.72) 1.39 9.62 6 0.36 (0.98) 6.90 *
+ Imatinib 5 mM 7.10 6 0.56 (0.72) 1.39 8.05 6 0.58 (0.82) 8.25 *
+ Dasatinib 2.5 mM 9.19 6 0.88 (0.93) 1.07 62.74 6 7.11 (6.36) 1.06
Doxorubicin 30.10 6 0.75 (1.00) 38.45 6 0.36 (1.28)
+ Nilotinib 1 mM 25.73 6 0.10 (0.85) 1.17 31.73 6 0.91 (1.05) 1.21
+ Nilotinib 2.5 mM 33.77 6 0.32 (1.12) 0.89 36.52 6 1.44 (1.21) 1.05
+ Nilotinib 5 mM 31.36 6 2.46 (1.04) 0.96 33.25 6 1.77 (1.10) 1.16
+ Imatinib 1 mM 31.52 6 0.75 (1.05) 0.95 42.18 6 2.02 (1.40) 0.91
+ Imatinib 2.5 mM 34.14 6 0.82 (1.13) 0.88 42.96 6 0.36 (1.43) 0.90
+ Imatinib 5 mM 32.77 6 0.56 (1.09) 0.92 38.75 6 0.58 (1.29) 0.99
+ Dasatinib 2.5 mM 27.33 6 1.57 (0.91) 1.10 32.47 6 1.33 (1.08) 1.18
aValues represent the mean6SD of at least three independent experiments performed in triplicate.
bFold resistance was the IC50 values for paclitaxel, vincristine, and doxorubicin of HEK293-pcDNA3.1 in the presence of either nilotinib, imatinib or dasatinib, or the
transfected cells HEK-MRP7-2 with or without the reversing agents, divided by the IC50 values for paclitaxel, vincristine, and doxorubicin of HEK293-pcDNA3.1 cells
without the reversing agents. Cell survival was determined by the MTT assay as described in ‘‘Section 2’’.
cDose-modifying factor was the ratio of IC50 values without reversal agent to the IC50 values with reversal agents. * Significantly different from the control transfected as
assayed by the Student’s t-test (P,0.05); ** P,0.01. The experiments were repeated at least three times.
doi:10.1371/journal.pone.0007520.t001
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7520Figure 3. The effect of imatinib (A), nilotinib (B) and dasatinib (C) on the sensitivity of MRP7-transfected HEK293 cells to paclitaxel.
Two cell lines, HEK293-pcDNA3.1 and HEK-MRP7-2, are represented as HEK293 and MRP7, respectively. After seeding and culturing cells for 24 h,
equal amounts of PBS or the reversal agents were added into HEK293-pcDNA3.1 cells (shown as and , respectively) and HEK-MRP7-2
cells (shown as and , respectively) 1 h before the addition of paclitaxel. The various concentrations of paclitaxel were indicated in the
figure. The final concentration for imatinib, nilotinib or dasatinib was 2.5 mM. The above figure shows a representative result for imatinib, nilotinib or
dasatinib.
doi:10.1371/journal.pone.0007520.g003
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increase in the uptake of paclitaxel. Therefore, the next experiment
was conducted to determine if the increase in paclitaxel accumu-
lationproducedbyimatinib and nilotinibwasduetoaninhibitionof
paclitaxel efflux. HEK-MRP7-2 cells and HEK293-pcDNA3.1 cells
were incubated with paclitaxel and a time course for intracellular
drug accumulation was determined (Fig. 5). As expected, HEK-
MRP7-2 cells released a significantly higher percentage of
accumulated paclitaxel compared to HEK293-pcDNA3.1 cells,
and the amount of paclitaxel that was effluxed increased with time.
The paclitaxel accumulation at 0 min of drug efflux was set as 1. At
60 min, in cells incubated in drug-free medium, ,60% of the
accumulated paclitaxel was exported from HEK-MRP7-2 cells in
the absence of imatinib or nilotinib. In contrast, almost all of the
paclitaxel was present insidethe HEK-MRP7-2 cellsincubated with
imatinib or nilotinib at a final concentration of 5 mM over different
time periods. For the control cells, the concentration of paclitaxel
subjected to efflux also increased with time, but the level of efflux
was only slightly less than that observed in cells transfected with
MRP7. In contrast, in the HE293-pcDNA3.1 cells, ,30% of the
paclitaxel was released after 60 min in the absence of the test
compounds. The incubation of the HEK293-pcDNA3.1 cells with
imatinib or nilotinib (5 mM) also inhibited the efflux of paclitaxel,
although the magnitude of the effect was significantly lower than
that observed for the HEK-MRP7-2 cells.
Discussion
This study was the first to identify that the BCR-Abl TKIs
imatinib and nilotinib, but not dasatinib, could reverse MRP7-
mediated MDR in a concentration-dependent manner.
HEK293 cells transfected with the MRP7 recombinant gene
HEK-MRP7-2, and HEK293-pcDNA3.1 cells transfected with
empty vector, were used for the tests of MRP7 efflux function.
These transfected cell lines have previously been used in studies
designed to determine the effects of cepharanthine on the reversal
Figure 4. The effect of imatinib (A) or nilotinib (B) on the
accumulation of [
3H]-paclitaxel in HEK293-pcDNA3.1 and HEK-
MRP7-2 cells. The intracellular paclitaxel accumulations in HEK293-
pcDNA3.1 and HEK-MRP7-2 cells were measured after the incubation
with 0.1 mM paclitaxel. Intracellular accumulation of paclitaxel in
HEK293-pcDNA3.1 cells in the absence of imatinib and nilotinib were
shown in the left bars (&). Intracellular accumulation of paclitaxel in the
presence of 5 mM of imatinib in HEK293-pcDNA3.1 cells was shown on
the right (%). Intracellular accumulation of paclitaxel in HEK-MRP7-2
cells in the presence of 5 mM of nilotinib was shown on the right ( ).
Each column represents the means (6SD). All experiments were done in
triplicate. * p,0.05, Student’s t test.
doi:10.1371/journal.pone.0007520.g004
Figure 5. The effect of imatinib (A) or nilotinib (B) on the
paclitaxel efflux in HEK293-pcDNA3.1 and HEK-MRP7-2 cells.
The percentage of the paclitaxel released was plotted as a function of
time. After 1 h of incubation of the TKIs, [
3H]-paclitaxel was co-
incubated in HEK293-pcDNA3.1 with TKI ( ) or without TKI
( ), and meanwhile in HEK-MRP7-2 cells with TKI ( )o r
without TKI ( ). Cells were washed and re-incubated in the
paclitaxel-free medium. At the time points of 0 min, 20 min, 60 min and
120 min, the cells were collected and the levels of [
3H]-paclitaxel were
determined by scintillation counting. The values at 0 min of drug efflux
were set as 1 for comparison to values measured from other time
points. Each point represents the means (6SD) of three separated
experiments done using triplicate samples.
doi:10.1371/journal.pone.0007520.g005
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Western blot analysis confirmed that the transfection of cells with
MRP7 was successful, as MRP7 proteins were expressed only in
HEK-MRP7-2 cells, and not in HEK293-pcDNA3.1 cells (Fig. 2).
The cell lines were exposed to the exact same experimental
conditions and procedures, and were cultured with the same
antineoplastic drugs for the same incubation time. It may be
argued that the MRP7-transfected cells expressed other proteins,
in addition to MRP7, such as P-gp, that may have contributed to
MDR. However, Western blot analysis indicated that neither the
HEK293-pcDNA3.1 control cell line, nor the HEK-MRP7-2
transfected cell line, expressed detectable levels of P-gp (Fig. 2),
which can also mediate MDR. In addition, MRP1 and BCRP
were undetectable in both control HEK293-pcDNA3.1 and
transfected HEK-MRP7-2 cells through Western blot analysis
(data not shown). Therefore, these results indicate that the HEK-
MRP7-2 transfected cell line specifically expressed MRP7, but
not P-gp, MRP, or BCRP.
Previously, it has been reported that cepharanthine and
nilotinib significantly reversed P-gp-mediated MDR in HEK-
MRP7-2 cells [9] and BCRP-overexpressing cell lines [24],
respectively. Since MRP7 and P-gp are similar in structure and
functional activity, we designed experiments to determine if
nilotinib could reverse MRP7-mediated drug resistance to
paclitaxel. Owing to the structural similarity between MRP7 and
P-gp, an earlier study indicated that some P-gp inhibitors were
able to significantly reverse paclitaxel resistance in HEK-MRP7-2
cells overexpressing MRP7 [9]. We found that nilotinib (2.5 mM)
significantly sensitized MRP7-transfected HEK293 cells to pacli-
taxel as it markedly decreased the IC50 of paclitaxel in MRP7-
trasnfected cells, compared to control cells. Although nilotinib is
an inhibitor of P-gp [24], this is not a confounding factor in our
experiments as the P-gp protein is not expressed in either
HEK293-pcDNA3.1 or HEK-MRP7-2 cells (Fig. 2).
In this study, we found that specific TKIs: 1) significantly
decreased resistance to paclitaxel in MRP7-overexpressing cells
(Table 1; Fig. 3), 2) did significantly sensitize the response to
paclitaxel in the empty vector transfected cells, but the effect was
significantly lower than that in the MRP7 transfected cells (Fig. 3),
and 3) did not significantly inhibit or induce MRP7 expression
(Fig. 2C and D). Overall, these findings tentatively suggest that of
the TKIs used in this study, imatinib and nilotinib are capable of
reversing MRP7-mediated resistance by inhibiting the function of
MRP7. Among the TKIs that were tested against paclitaxel, the
BCR-Abl TKIs imatinib and nilotinib at 5 mM completely
reversed MRP7-mediated paclitaxel resistance by a magnitude of
12.5- and 21.0-fold, respectively (Table 1). In contrast, another
BCR-Abl TKI, dasatinib, produced no significant reversal of
MRP7-mediated paclitaxel resistance (Table 1; Fig. 3C). Current-
ly, the explanation for the difference between dasatinib compared
to nilotinib or imatinib remains to be determined. One potential
approach that may yield insight into this issue would be that of
structural-activity relationship (SAR). Based on their chemical
structures (Fig. 1), dasatinib lacks a 2-phenylaminopyrimidine ring
that is present in the structures of nilotinib and imatinib. It is
possible that the absence of this ring in dasatinib could be an
important factor that differentiates dasatinib activity from that of
either nilotinib or imatinib. Detailed structure-function studies will
be required to delineate the SAR for the interaction of these TKIs
with MRP7-overexpressing cells. In addition, it was suggested that
the HEK293-pcDNA3.1 cells were also sensitized by co-admin-
istering nilotinib or imatinib (Table 1; Fig. 5). Such sensitization
could be due to possible endogenous efflux pumps in the HEK293-
pcDNA3.1 cells.
In order to extend the findings obtained with paclitaxel, we
examined the effect of specific TKIs on the response of MRP7-
expressing cells to another antineoplastic drug, vincristine, which is a
substrate for MRP7 [23]. Our results indicated that both nilotinib
and imatinib (2.5 mM) completely reversed MRP7-mediated vincris-
tine resistance by a factor of 6.8- and 6.9-fold, respectively (Table 1).
Thus, nilotinib and imatinib can significantly attenuate MRP7-
mediated resistance to not only paclitaxel, but also to vincristine. As
an additional control, we examined the effect of nilotinib and
imatinib on the response of MRP7-transfected cells to doxorubicin,
which is not a substrate for MRP7 [23]. The results indicated that
neither nilotinib nor imatinib (1, 2.5, and 5 mM) significantly altered
the response of cells to doxorubicin (Table 1). This finding suggests
that the actions of the TKIs in reversing MRP7-mediated resistance
are due to a specific effect on the MRP7 pump.
It is well established that MRP7, P-gp and MRP1 are all drug
efflux pumps responsible for the extracellular transport of a variety
of antineoplastic drugs. Consequently, when these pumps are
present in the tumor cells concurrently, each of the pumps
contributes to the efflux and decrease of intracellular drug
concentrations. This latter action ultimately leads to drug levels
that are no longer cytotoxic, leading to failure of therapy. For
instance, nilotinib has been identified as an inhibitor of P-gp and
the BCRP efflux pumps [24]. In the current study, it has also been
identified as a reversal agent for MRP7-mediated resistance to
paclitaxel. Our findings, provided that they can be translated to in
vivo function, suggest that specific TKIs may be useful in treating
cancer cells that have become resistant to treatment as a result of
MRP7 overexpression. The systemic exposures achieved at the
standard recommended doses of both imatinib (steady state Cmax/
Cmin 5.2 and 2.5 mM at 400 mg q.d.) and nilotinib (steady state
Cmax/Cmin 4.0 and 1.8 mM at 400 mg b.i.d.) are similar to the
concentrations that reversed drug resistance in the present study
[25,26]. Thus, it is possible that TKIs such as those used in this
study could be useful chemosensitizing drugs in the clinic for
specific patients. Clearly, in vivo studies are needed to evaluate the
effects of specific TKIs on the resistance of cancer cells to
antineoplastic drugs.
Future experiments, based on the current findings, include the:
1) determination of the effects of newly synthesized TKIs to
reverse MRP7-mediated drug resistance, and 2) analysis of the
effects of TKIs on the efflux activity of other ABC transporters.
In summary, the results of this study are the first to indicate that
the BCR-Abl TKIs imatinib and nilotinib, but not dasatinib, at
concentrations that did not produce cytotoxicity, significantly
reversed MRP7-mediated MDR to paclitaxel and vincristine.
Furthermore, these TKIs might be inhibitors for multiple MDR
efflux pumps, such as P-gp and BCRP for nilotinib [22]. In addition,
it is likely that imatinib and nilotinib reverse MDR in the HEK293-
MRP7 transfected cells by inhibiting the efflux activity of the MRP7
(ABCC10) transporter. Provided these results can be extended to
human cancer cells, they suggest that the TKIs could be useful in
treating patients that exhibit resistance to paclitaxel or vincristine as
a resultof MRP7.Therefore,TKIsmaybeusefulmodifiers of MDR
in cancer cells that overexpress P-gp, BCRP and/or MRP7 [22].
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